Veerhealth Care USFDA Push: ₹33 Cr Raise, Revenue Jumps 22%, Eyes US Market

Veerhealth Care Ltd.'s FY25 revenue climbed to ₹17.89 crore from ₹14.61 crore in FY24, a 22% increase. However, Profit After Tax saw a marginal dip to ₹0.39 crore from ₹0.41 crore.

Reader Takeaway: Revenue up on new orders; PAT dip and execution risks loom.

What just happened (today’s filing)

Veerhealth Care Ltd. has unveiled an investor presentation detailing its strategic growth trajectory, marked by a significant revenue jump and ambitious expansion plans.

The company posted revenue from operations of ₹17.89 crore for FY25, up from ₹14.61 crore in FY24. This growth was accompanied by securing new commercial and export orders.

However, Profit After Tax (PAT) saw a slight decrease, standing at ₹0.39 crore in FY25 compared to ₹0.41 crore in FY24. EBITDA also declined from ₹2.00 crore to ₹1.68 crore.

A major highlight is the USFDA registration obtained on January 3, 2024, which enables exports of Over-The-Counter (OTC) products to the United States market. The company is proposing to raise ₹3,300 lakh (₹33 crore) through a Rights Issue (₹2,500 lakh) and Term Loan (₹800 lakh) to fund this expansion.

These funds are earmarked for land acquisition and development (₹421 lakh), building construction (₹1,093.50 lakh), and plant and machinery (₹1,150.50 lakh).

Why this matters

The USFDA approval is a critical gateway, opening up the large and lucrative US market for Veerhealth Care's OTC product portfolio. This elevates the company's potential beyond domestic boundaries.

The planned capital expenditure of ₹33 crore signifies a robust commitment to scaling up manufacturing infrastructure. This capacity enhancement is crucial to meet anticipated demand from new orders and market expansion.

The backstory (grounded)

Veerhealth Care has been building its foundation, culminating in the crucial USFDA registration achieved in early January 2024. This milestone is pivotal for its international ambitions.

The company's strategy now focuses on leveraging this approval to enter the US market, supported by substantial investments in upgrading its manufacturing facilities.

What changes now

• US Market Access: The company can now export its OTC pharmaceutical products to the United States.
• Enhanced Capacity: The ₹33 crore fundraising will significantly boost its manufacturing infrastructure, including land, buildings, and machinery.
• Revenue Diversification: New commercial and export orders are expected to diversify revenue streams and improve market traction.
• Growth Projections: The company has guided for FY26 revenue between ₹35-40 crore, indicating strong future growth expectations.

Risks to watch

While projections are strong, the company faces inherent market risks and uncertainties that could affect actual results. Its ability to successfully implement its expansion strategy and technological integration is subject to various factors.

Execution risk remains a key concern, as translating plans into tangible growth depends on various known and unknown operational factors.

Peer comparison

Companies like Caplin Point Laboratories have successfully navigated international markets, focusing on specific regions and product segments. Strides Pharma Science demonstrates how a global manufacturing footprint and focus on regulated markets like the US can drive growth.

Veerhealth Care's USFDA approval positions it to follow a similar path, aiming to capture a share in the competitive US OTC market.

Context metrics (time-bound)

• Revenue from operations grew from ₹14.61 crore in FY24 to ₹17.89 crore in FY25.
• Profit After Tax (PAT) stood at ₹0.41 crore in FY24, slightly decreasing to ₹0.39 crore in FY25.
• EBITDA declined from ₹2.00 crore in FY24 to ₹1.68 crore in FY25.
• The company has provided a revenue guidance of ₹35-40 crore for FY26.

What to track next

• Successful execution of the ₹3,300 lakh (₹33 crore) fundraising plan.
• Performance and scaling of new commercial and export orders, particularly into the US market.
• Achievement of the FY26 revenue guidance of ₹35-40 crore and 10% PAT.
• Progress in manufacturing and export operations for medical devices under USFDA compliance.